Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients

被引:13
|
作者
Tsai, Kai-Fan [1 ,2 ]
Li, Lung-Chih [1 ,2 ,6 ]
Hsu, Chien-Ning [2 ,3 ,7 ]
Lin, Chih-Che [2 ,4 ]
Lin, Yu-Hung [2 ,4 ]
Cheng, Yu-Fan [2 ,5 ]
Wang, Chih-Chi [2 ,4 ]
Chen, Chao-Long [2 ,4 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, 123 Da Pei Rd, Kaohsiung 833, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Pharm, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Ctr, Dept Surg, Kaohsiung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung, Taiwan
[6] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 59卷 / 03期
关键词
chronic kidney disease; liver transplantation; mTOR inhibitor; renal preservation; urinary biomarkers; CHRONIC KIDNEY-DISEASE; LIPOCALIN NGAL; RAPAMYCIN; TACROLIMUS; EFFICACY; INJURY; STAGE; IMMUNOSUPPRESSION; PROLIFERATION; NEPHROPATHY;
D O I
10.1002/jcph.1334
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mammalian targets of rapamycin inhibitors (mTORIs), including sirolimus and everolimus, are used for minimizing calcineurin inhibitors after liver transplantation. However, head-to-head randomized comparisons of these 2 mTORIs are lacking. We assessed the differences in renoprotection and possible mechanisms between sirolimus and everolimus in liver transplant recipients. For this prospective cohort study, we recruited liver transplant recipients whose regimens were switched from tacrolimus to sirolimus or everolimus at a Taiwan medical center. Serial changes in estimated glomerular filtration rate (eGFR), urinary N-acetyl--D-glucosaminidase, neutrophil gelatinase-associated lipocalin, 8-hydroxy-2-deoxyguanosine, and transforming growth factor-1 during 1 year after mTORI conversion were compared within and between groups. In the 61 patients analyzed, no significant change in eGFR occurred within 12 months after conversion in both mTORI groups. Among patients with baseline eGFR <60 mL/min/1.73 m(2), eGFR improved at 6 months and 1 year after conversion (+12.3 and +12.0 mL/min/1.73 m(2), both P < .05). Urinary N-acetyl--D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +/- 137.6 and -62.0 +/- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +/- 7763.5 ng/g creatinine; P < .05). Neither transforming growth factor-1 nor 8-hydroxy-2 '-deoxyguanosine changed significantly. In conclusion, the renoprotective effect of mTORI conversion was significant in liver transplant recipients with renal insufficiency, which was similar for sirolimus and everolimus, in the first year and may be associated with ameliorated tubular injury. Available evidence remains insufficient to determine which mTORI conversion therapy is more effective in renoprotection in the long run.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 50 条
  • [21] Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients
    Nair, S
    Eason, J
    Loss, G
    [J]. LIVER TRANSPLANTATION, 2003, 9 (02) : 126 - 129
  • [22] Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients
    Rogers, Christin C.
    Johnson, Scott R.
    Mandelbrot, Didier A.
    Pavlakis, Martha
    Horwedel, Timothy
    Karp, Seth J.
    Egbuna, Ogo
    Rodrigue, James R.
    Chudzinski, Robyn E.
    Goldfarb-Rumyantzev, Alexander S.
    Hanto, Douglas W.
    Curry, Michael P.
    [J]. CLINICAL TRANSPLANTATION, 2009, 23 (06) : 887 - 896
  • [23] Replacement of calcineurin-inhibitors with sirolimus to preserve renal function in stable cardiac transplant recipients
    Raichlin, F.
    Khalpey, Z.
    Clavell, A. L.
    Edwards, B. S.
    Frantz, R. P.
    Wagner, J. A.
    Rodeheffer, R. J.
    Kushwaha, S. S.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (02): : S138 - S138
  • [24] Improvement of Renal Function After the Switch from a Calcineurin Inhibitor to Everolimus in Liver Transplant Recipients with Chronic Renal Dysfunction
    Castroagudin, Javier F.
    Molina, Esther
    Romero, Rafael
    Otero, Esteban
    Tome, Santiago
    Varo, Evaristo
    [J]. LIVER TRANSPLANTATION, 2009, 15 (12) : 1792 - 1797
  • [25] Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: Effect on renal function and proteinuria
    Morales, J.
    Fierro, A.
    Benavente, D.
    Zehnder, C.
    Ferrario, M.
    Contreras, L.
    Herzog, C.
    Buckel, E.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (03) : 591 - 593
  • [26] Clinical Experience of Late Conversion From Antimetabolites With Standard Exposure Calcineurin Inhibitors to Everolimus With Calcineurin Inhibitor Minimization in Stable Kidney Transplant Recipients With Good Renal Function
    Uchida, J.
    Iwai, T.
    Kuwabara, N.
    Kabei, K.
    Nishide, S.
    Yamasaki, T.
    Naganuma, T.
    Kumada, N.
    Takemoto, Y.
    Nakatanti, T.
    [J]. TRANSPLANTATION PROCEEDINGS, 2016, 48 (03) : 775 - 780
  • [27] Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients
    Martinez-Mier, Gustavo
    Mendez-Lopez, Marco Tulio
    Estrada-Oros, Jorge
    Budar-Fernandez, Luis F.
    Soto-Gonzalez, Juan I.
    Mendez-Machado, Gustavo F.
    Vinas Dozal, Julio Cesar
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (05) : 635 - 638
  • [28] Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low dose calcineurin inhibitors
    Dubay, Derek
    Lilly, Leslie
    Smith, Robert
    Levy, Gory A.
    Therapondos, George
    [J]. HEPATOLOGY, 2007, 46 (04) : 495A - 495A
  • [29] IMPROVEMENT IN RENAL FUNCTION FOLLOWING CONVERSION TO SIROLIMUS IN LIVER TRANSPLANT RECIPIENTS WITH CHRONIC RENAL INSUFFICIENCY
    Leise, Michael D.
    Asrani, Sumeet K.
    Rosen, Charles B.
    Pedersen, Rachel
    Therneau, Terry M.
    Kim, W. Ray
    [J]. HEPATOLOGY, 2009, 50 (04) : 578A - 578A
  • [30] IMMUNOREGULATORY EFFECTS OF CONVERSION FROM TACROLIMUS TO SIROLIMUS IN LIVER TRANSPLANT RECIPIENTS
    Levitsky, Josh
    Mathew, James M.
    Flaa, Catherine W.
    Rosen, Anne
    Tambur, Anat R.
    Miller, Joshua
    [J]. HEPATOLOGY, 2009, 50 (04) : 568A - 568A